Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort

JAMA

Volumn 311, Issue 14, 2014, Pages 1416-1423

  Kavousi, Maryam ^a   Leening, Maarten J G ^a   Nanchen, David ^b   Greenland, Philip ^c   Graham, Ian M ^d   Steyerberg, Ewout W ^a   Ikram, M Arfan ^a   Stricker, Bruno H ^a,e   Hofman, Albert ^a   Franco, Oscar H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c NORTHWESTERN UNIVERSITY   (United States)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e Inspectorate of Health Care   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMPARATIVE STUDY; EUROPE; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MALE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

AGED; AMERICAN HEART ASSOCIATION; CARDIOLOGY; CARDIOVASCULAR DISEASES; COHORT STUDIES; EUROPE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MODELS, THEORETICAL; NETHERLANDS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SOCIETIES, MEDICAL; STROKE; UNITED STATES;

EID: 84898765754     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.2632     Document Type: Article

References (26)

1. Go AS, Mozaffarian D, Roger VL, et al American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127(1):143-152.
2. Nichols M, Townsend N, Scarborough P, et al. European Cardiovascular Disease Statistics 2012. Brussels, Belgium: European Heart Network and European Society of Cardiology; 2012.
3. Yusuf S, Hawken S, Ounpuu S, et al INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952. (Pubitemid 39208455)
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
5. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online November 12, 2013]. Circulation. doi:10.1161/01.cir.0000437738.63853.7a.
6. Reiner Z, Catapano AL, De Backer G, et al European Association for Cardiovascular Prevention and Rehabilitation; ESC Committee for Practice Guidelines 2008-2010 and 2010-2012 Committees. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769-1818.
7. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online November 12, 2013]. Circulation. doi:10.1161/01.cir. 0000437741.48606.98.
8. Ioannidis JPA. More than a billion people taking statins? potential implications of the new cardiovascular guidelines. JAMA. 2014;311(5): 463-464.
9. Keaney JF Jr, Curfman GD, Jarcho JA. A pragmatic view of the new cholesterol treatment guidelines. N Engl J Med. 2014;370(3):275-278.
10. McCarthy M. New US prevention guidelines focus on overall risk of cardiovascular disease. BMJ. 2013;347:f6858.
11. Psaty BM,Weiss NS. 2013 ACC/AHA guideline on the treatment of blood cholesterol: a fresh interpretation of old evidence. JAMA. 2014;311(5):461-462.
12. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;382(9907):1762-1765.
13. Hofman A, Darwish Murad S, van Duijn CM, et al. The Rotterdam Study: 2014 objectives and design update. Eur J Epidemiol. 2013;28(11):889-926.
14. Leening MJG, Kavousi M, Heeringa J, et al. Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study. Eur J Epidemiol. 2012;27(3):173-185.
15. Wieberdink RG, Ikram MA, Hofman A, Koudstaal PJ, Breteler MMB. Trends in stroke incidence rates and stroke risk factors in Rotterdam, the Netherlands from 1990 to 2008. Eur J Epidemiol. 2012;27(4):287-295.
16. Framingham Heart Study. Hard coronary heart disease (10-year risk). http://www .framinghamheartstudy.org/risk-functions /coronary-heart-disease/ hard-10-year-risk.php. Accessed March 17, 2014.
17. Conroy RM, Pyörälä K, Fitzgerald AP, et al SCORE Project Group. Estimation of 10-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987-1003. (Pubitemid 36712275)
18. Perk J, De Backer G, Gohlke H, et al European Association for Cardiovascular Prevention and Rehabilitation; ESC Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 9 societies and by invited experts). Eur Heart J. 2012;33(13):1635-1701.
19. Mihaylova B, Emberson J, Blackwell L, et al Cholesterol Treatment Trialists Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-590.
20. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419.
21. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.
22. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180-187. (Pubitemid 32640849)
23. Hense HW, Schulte H, Löwel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J. 2003;24(10):937-945. (Pubitemid 36559987)
24. Pyörälä K. Assessment of coronary heart disease risk in populations with different levels of risk. Eur Heart J. 2000;21(5):348-350. (Pubitemid 30107550)
25. Vikhireva O, Pajak A, Broda G, et al. SCORE performance in Central and Eastern Europe and former Soviet Union: MONICA and HAPIEE results. Eur Heart J. 2014;35(9):571-577.
26. Graham IM, Cooney MT. Risks in estimating risk. Eur Heart J. 2014;35(9):537-539.